*Refresh the page if the below document does not appear.
Zydus receives USFDA affirmation to market Cariprazine capsules
Zydus has received final approval from the regulatory body to market Capriprazine Capsules USP 1.5 mg, 3 mg, 4.5 mg, and 6 mg dose capsules and indicated as an atypical antipsychotic and also for acute treatment of maniac or mixed episodes of bipolar disorder.
Astrazeneca Pharma India Ltd's counter sees increase in volume
67221 shares of Astrazeneca Pharma India Ltd were traded on the NSE, an increase of 11.45 times the two-week daily average volume of 5870 shares. The share price increased by 6.50% to Rs.3,300.00.
German firm opens its new CoE in Genome Valley, Hyderabad
DFE Pharma, a provider of pharmaceutical and nutraceutical excipient solutions launched its Centre of Excellence designated as C2F i.e Closer to the formulator. The company deals with pre registration work, including development, scale up and so on, particularly related to OSD’s.
Local anesthesia drug reduces risk of metastasis after breast cancer surgury
A team of researchers from Tata Memorial Centre, Mumbai has shown that a local Anesthesia drug lignocaine has been found to improve the cure rates and increased survival rates in patients suffering from breast cancer.
US FDA issues form 483 to Ajanta Pharma Dahej facility
The company fell 1.61% to ₹ 1372.60 after the US regulatory body inspected it’s Dahej manufacturing unit and issued it Form 483 with two procedural observations.
Amgen pill reduces risk of lung cancer progression by 34%
Although Lumakras showed no significant difference in overall survival compared to one other treatment, the pill did reduce the risk of disease progression in patients with advance lung cancer by 34%.
Algeron pharmaceuticals receives consent for Phase 1 clinical study of DMT
The company announced the grant of
permission to conduct a phase 1 clinical
study of an intravenous formulation of DMT
indicated for the treatment of stroke.